financetom
Business
financetom
/
Business
/
Update: Market Chatter: Grifols' Family Won't Welcome Other Takeover Bids as Brookfield Walks Away
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Market Chatter: Grifols' Family Won't Welcome Other Takeover Bids as Brookfield Walks Away
Nov 27, 2024 6:31 AM

09:13 AM EST, 11/27/2024 (MT Newswires) -- (Updates with Brookfield statement in the second paragraph.)

Grifols ( GRFS ) has decided not to welcome a new takeover bid by a third-party as Brookfield Asset Management ( BAM ) intends to walk away from its plan to acquire the company, Bloomberg reported Wednesday, citing the Grifols ( GRFS ) family.

In a statement sent to MT Newswires, Brookfield confirmed "it is not in a position to continue with a potential offer for Grifols ( GRFS )."

Brookfield decided to stop months of talks after failing to reach a deal with the board of Grifols ( GRFS ) on valuation, the report added, citing unnamed people familiar with the plan.

Brookfield had arranged financing for the deal and prepared a turnaround plan for the business, the report said, citing the people.

"The family will not back another take private transaction," the news outlet quoted a Grifols' ( GRFS ) family spokesperson as saying by phone. "We are very pleased with all the letters we've received from existing shareholders telling us the company is worth more and we will continue working so that the company's value increases even more."

Grifols ( GRFS ) didn't immediately respond to MT Newswires' request for comment.

GRFS shares were down more than 13% in recent Wednesday premarket activity.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Singapore Airlines plane made 'dramatic drop', people flung into lockers, says passenger
Singapore Airlines plane made 'dramatic drop', people flung into lockers, says passenger
May 21, 2024
May 21 (Reuters) - There was little warning of the chaos that was about to be unleashed onboard Singapore Airlines flight SQ321. With around three hours left on the journey from London to Singapore, Malaysian student Dzafran Azmir got the uneasy feeling the Boeing 777-300R plane was tilting upwards and beginning to shake. The 28-year-old braced himself and checked he...
Greenbrier Appoints Names Michael Donfris CFO
Greenbrier Appoints Names Michael Donfris CFO
May 21, 2024
09:17 AM EDT, 05/21/2024 (MT Newswires) -- Greenbrier (GBX) said Tuesday it has named Michael Donfris as chief financial officer. Donfris most recently served as CFO at R.J. Corman Railroad, Greenbrier said. Donfris will initially be senior vice president, finance, and will become CFO in July after Greenbrier files its report for the quarter ending May 31, the company said....
Update: Market Chatter: Shell, Exxon Mobil Mulling Bids for Stake in Galp Energia's Offshore Namibia Site
Update: Market Chatter: Shell, Exxon Mobil Mulling Bids for Stake in Galp Energia's Offshore Namibia Site
May 21, 2024
09:18 AM EDT, 05/21/2024 (MT Newswires) -- (Updates with additional details.) Shell (SHEL) and Exxon Mobil ( XOM ) are among the energy companies considering bids for a 40% stake in Galp Energia's Mopane oil field off the coast of Namibia, Bloomberg News reported Tuesday, citing sources with knowledge of the matter. TotalEnergies (TTE) and Equinor ( EQNR ) are...
Alvotech and Dr. Reddy's Partner to Commercialize Biosimilar Candidate Denosumab
Alvotech and Dr. Reddy's Partner to Commercialize Biosimilar Candidate Denosumab
May 21, 2024
09:20 AM EDT, 05/21/2024 (MT Newswires) -- Alvotech ( ALVO ) and Dr. Reddy's Laboratories (RDY) said Tuesday that they have partnered to commercialize AVT03, or denosumab, a biosimilar candidate to Prolia and Xgeva that addresses certain skeletal-related diseases. Financial details of the deal remain undisclosed. The agreement requires Alvotech ( ALVO ) to develop and manufacture the product, while...
Copyright 2023-2026 - www.financetom.com All Rights Reserved